Predict your next investment

HEALTHCARE | Drug Discovery
visterrainc.com

See what CB Insights has to offer

Stage

Acquired | Acquired

Total Raised

$124.99M

Valuation

$0000 

About Visterra

Visterra, formerly Parasol Therapeutics, is a biotechnology company that uses its Hierotope Platform to identify unique disease targets and design effective therapeutics. The company's technology is powered by computational tools and techniques, called Atomic Interaction Network (AIN) analysis, which uniquely identifies an area, or epitope, on the target site that is fundamental to its structure and function. This ideal epitope, or hierotope, becomes the target against which the company designs a novel therapeutic to effectively and durably combat the disease. The company is currently focused on therapeutics for infectious diseases and its lead product candidate, VIS410, is a broad spectrum human monoclonal antibody for the prevention and treatment of both seasonal and pandemic influenza. The company's second product candidate, VIS513, is a human monoclonal antibody for the treatment of dengue fever that has been shown to broadly neutralize all four dengue virus serotypes.

Visterra Headquarter Location

One Kendall Square Suite B3301

Cambridge, Massachusetts, 02139,

United States

617-498-1070

Latest Visterra News

2019 Glomerulonephritis Pipeline Review, H2 - Biogen Inc, Omeros Corp, Pfizer Inc & Visterra Inc - ResearchAndMarkets.com

Jan 9, 2020

January 09, 2020 04:57 AM Eastern Standard Time Glomerulonephritis is also known as glomerular nephritis (GN) or glomerular disease. It is a disease of the kidney, characterized by inflammation of the glomeruli. Causes of glomerulonephritis include Streptococcal infection of the throat known as strep throat, immune diseases, such as lupus, Type 1 diabetes and type 2 diabetes and viruses, such as HIV, hepatitis B virus, and hepatitis C virus. Factors that increase chances of getting glomerulonephritis include family history of glomerulonephritis, the presence of a known cause of glomerulonephritis and high blood pressure. Common symptoms of glomerulonephritis are blood in the urine (dark, rust-colored, or brown urine), foamy urine, swelling (edema) of the face, eyes, ankles, feet, legs, or abdomen. Treatment will depend on the cause of glomerulonephritis such as medications, lifestyle changes, dialysis and transplant. Report Highlights The Publisher's Pharmaceutical and Healthcare latest pipeline guide Glomerulonephritis - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Glomerulonephritis (Genito Urinary System And Sex Hormones), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The Glomerulonephritis (Genito Urinary System And Sex Hormones) pipeline guide also reviews of key players involved in therapeutic development for Glomerulonephritis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 3, 17, 11, 20, 4 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 4 molecules, respectively. Glomerulonephritis (Genito Urinary System And Sex Hormones) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from The Publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. Scope The pipeline guide provides a snapshot of the global therapeutic landscape of Glomerulonephritis (Genito Urinary System And Sex Hormones). The pipeline guide reviews pipeline therapeutics for Glomerulonephritis (Genito Urinary System And Sex Hormones) by companies and universities/research institutes based on information derived from company and industry-specific sources. The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. The pipeline guide reviews key companies involved in Glomerulonephritis (Genito Urinary System And Sex Hormones) therapeutics and enlists all their major and minor projects. The pipeline guide evaluates Glomerulonephritis (Genito Urinary System And Sex Hormones) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. The pipeline guide encapsulates all the dormant and discontinued pipeline projects. The pipeline guide reviews latest news related to pipeline therapeutics for Glomerulonephritis (Genito Urinary System And Sex Hormones) Reasons to buy Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. Find and recognize significant and varied types of therapeutics under development for Glomerulonephritis (Genito Urinary System And Sex Hormones). Classify potential new clients or partners in the target demographic. Develop tactical initiatives by understanding the focus areas of leading companies. Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics. Formulate corrective measures for pipeline projects by understanding Glomerulonephritis (Genito Urinary System And Sex Hormones) pipeline depth and focus of Indication therapeutics. Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope. Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline. Key Topics Covered: Glomerulonephritis - Drug Profiles

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Visterra Patents

Visterra has filed 35 patents.

The 3 most popular patent topics include:

  • Immune system
  • Immunology
  • Monoclonal antibodies
patents chart

Application Date

Grant Date

Title

Related Topics

Status

11/10/2016

11/9/2021

Molecular biology, Antibiotics, Immune system, Psychiatric diagnosis, Protein families

Grant

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

Application Date

11/10/2016

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Grant Date

11/9/2021

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Title

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Related Topics

Molecular biology, Antibiotics, Immune system, Psychiatric diagnosis, Protein families

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Status

Grant

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.